Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MLNR | O43193 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL165478 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KMT2AMLNR | |
| SCHEMBL98019 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3KMT2AMLNR | |
| Methylamine SCHEMBL6327312 | 0.97 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KMT2AMLNR | |
| SCHEMBL4139336 | 0.92 | KMT2A (0.46) | SLC6A2SLC6A4SLC6A3KMT2AMLNR | |
| SCHEMBL12546727 | 0.88 | KMT2A (0.44) | SLC6A2SLC6A4SLC6A3KMT2AMLNR | |
| SCHEMBL12546791 | 0.88 | KMT2A (0.44) | SLC6A2SLC6A4SLC6A3KMT2AMLNR | |
| SCHEMBL13536715 | 0.86 | KMT2A (0.46) | SLC6A2SLC6A4SLC6A3KMT2AMLNR | |
| Mandelic Acid SCHEMBL6378790 | 0.85 | LMNA (0.46) | SLC6A2SLC6A4SLC6A3KMT2AMLNR | |
| Mandelic Acid SCHEMBL6376919 | 0.85 | LMNA (0.46) | SLC6A2SLC6A4SLC6A3KMT2AMLNR | |
| SCHEMBL14353971 | 0.83 | KMT2A (0.46) | SLC6A2SLC6A4SLC6A3KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405917-B1 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | SALTIGO GMBH (DE) | 2013-08-14 | — | — | EP | claimed |
| US-8258338-B2 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2012-09-04 | — | — | US | claimed |
| CN-102627572-A | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG | 2012-08-08 | — | — | CN | claimed |
| EP-1720852-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE 1-SUBSTITUTED-3-AMINOALCOHOLS | LONZA AG (CH) | 2012-07-11 | — | — | EP | claimed |
| US-7973182-B2 | enantiomerically pure 1-substituted-3-amino-alcohols, particularly of (S)-(-)- and (R)-(+)-3-N-methylamino-1-(2-thienyl)-1-propanol, by asymmetrically hydrogenating salts of a carboxylic acids with an aminoketone of the formula: | LONZA LTD. (CH) | 2011-07-05 | — | — | US | claimed |
| CN-101124196-B | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG | 2011-05-11 | — | — | CN | claimed |
| US-7553970-B2 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2009-06-30 | — | — | US | claimed |
| US-20090156833-A1 | Process for the Preparation of Enantiomerically Pure 1-Substituted-3-Aminoalcohols | LONZA AG (CH) | 2009-06-18 | — | — | US | claimed |
| US-20080154047-A1 | Process For the Preparation of Enantiomerically Pure1-Substitued-3-Aminoalcohols | LONZA AG (CH) | 2008-06-26 | — | — | US | claimed |
| CN-101124196-A | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2008-02-13 | — | — | CN | claimed |
| CN-101012219-A | Method of preparing dulouxetine | UNIV TIANJIN (CN) | 2007-08-08 | — | — | CN | claimed |
| CN-1922168-A | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | LONZA AG (CH) | 2007-02-28 | — | — | CN | claimed |
| EP-1566383-A1 | Process for the preparation of enantiomerically pure 1-substituted-3-aminoalcohols | Lonza AG (CH) | 2005-08-24 | — | — | EP | claimed |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-09-16 | — | — | US | claimed |
| CN-1497048-A | Method for preparing 3-heteroarylradical-3-hydroxy-propionic acid derivative | 拜尔公司 | 2004-05-19 | — | — | CN | claimed |
| EP-1405917-A2 | Process for the production of 3-Heteroaryl-3-hydroxy-propionic acid derivatives by enantioselective microbial reduction | Bayer Chemicals AG (DE) | 2004-04-07 | — | — | EP | claimed |
| WO-2004005307-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3-N-METHYLAMINO-1-(2-THIENYL)-1-PROPANOL | LONZA AG (CH) | 2004-01-15 | — | — | WO | claimed |
| US-10941138-B2 | Quinoline and isoquinoline derivatives for treating pain and pain related conditions | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2021-03-09 | — | — | US | disclosed |
| US-20030225153-A1 | Process for preparing arylaminopropanols | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| EP-1346977-A1 | Method for producing aryl-aminopropanols | Bayer Aktiengesellschaft (DE) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225153-A1 | Process for preparing arylaminopropanols | AHR, CYP1A1, CYP1A2 | SLC6A2 1337/4885SLC6A4 1738/4885SLC6A3 1529/4885 |
| US-10941138-B2 | Quinoline and isoquinoline derivatives for treating pain and pain related conditions | CACNA1B, SCN2A, CACNA1C | SLC6A2 15/4885SLC6A4 129/4885SLC6A3 154/4885 |
| US-20090156833-A1 | Process for the Preparation of Enantiomerically Pure 1-Substituted-3-Aminoalcohols | CYP2S1, AKR1C3, ADSL | SLC6A2 3369/4885SLC6A4 3037/4885SLC6A3 2109/4885 |
| US-20040181058-A1 | Process for preparing 3-heteroaryl-3-hydroxypropanoic acid derivatives | HPD, HAAO, GRHPR | SLC6A2 1405/4885SLC6A4 1298/4885SLC6A3 874/4885 |
| US-20080154047-A1 | Process For the Preparation of Enantiomerically Pure1-Substitued-3-Aminoalcohols | ADH1A, ADH1C, ALDH7A1 | SLC6A2 3361/4885SLC6A4 3028/4885SLC6A3 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.